Targacept Inc. (NASDAQ:CBIO)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Thursday. They presently have a $3.50 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 186.89% from the company’s previous close.
Separately, Rodman & Renshaw started coverage on Targacept in a report on Thursday, June 30th. They issued a “buy” rating and a $3.50 price target for the company.
Targacept (NASDAQ:CBIO) opened at 1.22 on Thursday. Targacept has a 12-month low of $1.12 and a 12-month high of $6.04. The stock’s 50 day moving average is $1.25 and its 200 day moving average is $1.44. The stock’s market capitalization is $14.44 million.
Targacept (NASDAQ:CBIO) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.11. Targacept had a negative return on equity of 62.53% and a negative net margin of 4,155.13%. Equities research analysts forecast that Targacept will post ($1.40) EPS for the current fiscal year.
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Targacept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Targacept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.